Enlivex Therapeutics Ltd. (ENLV) NASDAQ
0.73
-0.0169(-2.26%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.73
-0.0169(-2.26%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
71
First IPO Date
July 31, 2014
| Name | Title | Pay | Year Born |
| Oren Hershkovitz | Chief Executive Officer | 273,600 | 1977 |
| Shachar Shlosberger | Chief Financial Officer | 126,000 | 1977 |
| Dror Mevorach | Founder and Scientific Advisor | 180,000 | 1956 |
| Shai Novik | Executive Chairman | 528,000 | 1966 |
| Einat Galamidi | Chief Medical Officer | 0 | 1974 |
| Veronique Amor-Baroukh | Senior Director of Operations | 0 | N/A |
| Sigal Arad | Director of Human Resources | 0 | N/A |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.